Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
ACC 23: Statins to Protect Heart During Cancer Treatment: The STOP-CA Trial
Author(s): Marielle Scherrer-Crosbie Added: 1 year ago
ACC.23/WCC — In this succinct late-breaking science interview, Investigator, Dr Marielle Scherrer-Crosbie (Hospital of the University of Pennsylvania, US) discusses the results from the STOP-CA trial (Massachusetts General Hospital). This randomized phase II trial aims to investigate whether atorvastatin, a commonly prescribed statin drug for reducing cholesterol levels, can protect the heart… View more

Heart Failure

Prevention & Chronic Conditions
Author(s): Mark Sweeney , Angela Yiu , Alexander Lyon Added: 3 years ago
Cancer and the anti-cancer treatments prescribed by oncologists have long been known to have significant effects on muscle, causing a catabolic muscle wasting state and resulting in widespread and progressive atrophy of most muscle groups.1 This process contributes significantly to the cancer cachexia seen in up to 80% of all patients with cancer, resulting in progressive weight loss, loss of… View more

Heart Failure
Author(s): Carine E Hamo , Michelle W Bloom Added: 3 years ago
Heart disease and cancer are the two leading causes of death, together accounting for almost 50 % of deaths in the US.1 Unfortunately, the tremendous success in improving cancer survival is often attenuated by downstream cardiovascular complications from cancer therapy. Acute cardiac toxicity may limit the ability to use life-saving cancer therapy and chronic toxicity limits overall survival. As… View more

Heart Failure

CV Disease in Special Populations
Jose Alvarez-Cardona
Research Area(s) / Expertise:

Heart Failure

Cardio-oncology

 Job title: Cardiologist
Dr Jose Alvarez-Cardona is aCardiologist and Assistant Professor atNew York University School of Medicine, New York, US.He received his medical degree from University of Puerto Rico School of Medicine.He specialises in cardiomyopathy and heart failure. His specialities include cardiac amyloidosis, cardiomyopathy and heart failure, congestive heart failure, heart transplant and left ventricular… View more
Author(s): Edoardo Bertero , Pietro Ameri , Christoph Maack Added: 3 years ago
Heart failure (HF) and cancer represent two major causes of morbidity and mortality in developed countries.1,2 The prevalence of these conditions is growing as the age of the population and the burden of shared risk factors, such as diabetes and obesity, are constantly increasing. In past decades, the field of cardio-oncology has predominantly focused on prevention and treatment of cardiovascular… View more

Heart Failure

CV Disease in Special Populations
Subclinical Left Ventricular Dysfunction During Chemotherapy
Author(s): Martin Nicol , Mathilde Baudet , Alain Cohen-Solal Added: 3 years ago
Advances in the early detection and treatment of cancer have improved overall survival in cancer patients. Nevertheless, cardiovascular diseases appear as the major cause of morbidity and mortality among cancer survivors.1 Left ventricular (LV) dysfunction and/or heart failure are the most common cardiovascular complications after administration of chemotherapies. The term ‘cardiotoxicity’ is… View more

Heart Failure

CV Disease in Special Populations
Imaging in Women with Heart Failure: Sex-specific Characteristics and Current Challenges
Author(s): Isabella Leo , Eleni Nakou , Antonio de Marvao , et al Added: 1 year ago

Imaging & Diagnostics

Heart Failure
Author(s): Radek Pudil Added: 3 years ago
Cardiovascular (CV) disease and cancer remain the two most common causes of mortality in developed countries. According to recent data from the American Cancer Society, the lifetime probability of being diagnosed with an invasive cancer is higher for men (43 %) than for women (38 %).1 Within the last few decades the progress in the treatment of malignant diseases significantly improved survival… View more

Heart Failure

Prevention & Chronic Conditions
Author(s): Alessandra Cuomo , Alessio Rodolico , Amalia Galdieri , et al Added: 3 years ago
The increasing progress in cancer therapies has reduced mortality rates for many cancers. Unfortunately, many life-saving therapies are burdened by the risk of cardiotoxicity (CTX). The cardiovascular system appears to be particularly susceptible to the action of many anti-neoplastic drugs, which may cause vasospastic or thromboembolic ischaemia, arterial hypertension, dysrhythmia, and left… View more

Heart Failure

CV Disease in Special Populations
Pirfenidone for Lung and Cardiac Disorders
Author(s): Alberto Aimo , Giosafat Spitaleri , Dario Nieri , et al Added: 2 years ago

Heart Failure